Research by Huck and McLean (1975) demonstrated that the covariance-adjusted score is more powerful than the simple difference score, yet recent reviews indicate researchers are equally likely to use ...
Generally, the randomization for phase II trials is between two regimens, tumor response is the end point of interest, and the goal is to determine whether one experimental regimen should be brought ...
Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients Single-arm phase II trials may not be appropriate for testing cytostatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback